THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
|
|
- Roy Warner
- 5 years ago
- Views:
Transcription
1 THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016
2 There is growing distrust of pharma in light of several recent and dramatic increases in drug prices in the US. Global US-based patient group specialising in diabetes in 2016, patientview is publishing 20 corporate reputation of pharma reports, analysing the results from the 1,075 patient groups responding to the 2015 survey. specialty reports: cancer I circulatory conditions I diabetes I hiv/aids I hepatitis I neurological conditions I mental health I respiratory conditions I skin conditions I rare diseases (10 reports) geographic-region reports: europe I eastern europe I germany I global I italy I latin america I nordic I spain I uk I usa (10 reports)
3 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID DIABETES PATIENT GROUPS SAY ABOUT PHARMA IN 2015? Summary of the industry-wide findings (as judged by diabetes patient groups) Page 3 SOME POINTS ABOUT THE DIABETES CORPORATE RANKINGS Page 8 WHAT CAN PHARMA COMPANIES DO TO IMPROVE THEIR CORPORATE REPUTATION? Page 9 COMMENTS FROM DIABETES PATIENT GROUPS, 2015 Page 10 METHODOLOGY OF THE PATIENT-GROUP SURVEY Page 11 APPENDIX 1: Data on how diabetes patient groups see the pharmaceutical industry in 2015 Page 12 APPENDIX 2: Rankings of the 21 pharma companies for each of the six indicators of corporate reputation, as perceived by diabetes patient groups in 2015 Page 17 APPENDIX 3: Profiles of the 21 pharma companies, as perceived by diabetes patient groups in 2015 Page 26 APPENDIX 4: Profile of the 139 respondent diabetes patient groups Page 49
4 LIST OF TABLES AND CHARTS BASED ON THE VIEWS OF DIABETES PATIENT GROUPS, 2015 Percentage of diabetes patient groups claiming familiarity with the company Page 2 Percentage of diabetes patient groups claiming familiarity with the company, and which also worked with it Page 2 Percentage of patient groups of different therapy areas worldwide stating that the pharma industry had an Excellent or Good corporate reputation in 2015 ENSURING PATIENT SAFETY PATIENT CENTRICITY BEING TRANSPARENT HAVING INTEGRITY MANAGING ADVERSE NEWS ABOUT PRODUCTS PROVIDING SERVICES BEYOND THE BUSINESS REMIT Page 3 Page 5 Page 5 Page 6 Page 6 Page 7 Page 7 Diabetes patient groups can partner with many pharma companies Page 8 If a pharma company wishes to improve its corporate reputation with patients and patient groups, which single strategy from the list below do you think would be MOST IMPORTANT for the company to follow? Please select only ONE option How do you think your organisation s members (or the people you represent) would rate the corporate reputation of the following healthcare sectors in 2015? Page 9 Page 13 What do you think has happened to the corporate reputation of the pharma industry over the past five years? Page 14 How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups)? How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups)? Page 15 Page 16 Companies with the most effective patient-centred strategy (rankings of 21 companies, 2015) Page 18 Companies providing the best high-quality patient information (rankings of 21 companies, 2015) Page 19 Companies with the best record on patient safety (rankings of 21 companies, 2015) Page 20 Companies with the most-useful high-quality products (rankings of 21 companies, 2015) Page 21 Companies with the best record of transparency (rankings of 21 companies, 2015) Page 22 Companies with the best record on integrity (rankings of 21 companies, 2015) Page 23 Rankings of the 21 pharmaceutical companies in 2015, ALPHABETIC ORDER Page 24 Rankings of the 21 pharmaceutical companies in 2015, HIGHEST TO LOWEST Page 25 Profile of the 139 respondent patient groups with an interest in diabetes 2015, by country Page 50 Profile of the 139 respondent patient groups with an interest in diabetes 2015, by geographic remit Page 50
5 LIST OF TABLES AND CHARTS CONTINUED AbbVie page 28 Actavis page 29 Amgen page 30 AstraZeneca page 31 Bayer page 32 Boehringer Ingelheim page 33 B-MS page 34 Eli Lilly page 35 GSK page 36 Janssen page 37 Menarini page 38 Merck & Co (US) page 39 Novartis page 40 Novo Nordisk page 41 Pfizer page 42 Roche page 43 Sandoz page 44 Sanofi page 45 Servier page 46 Takeda page 47 Teva page 48 profiles of the 21 companies, according to the diabetes patient groups familiar with these companies, or which have worked with them Each profile contains... company background information Annual revenue (latest-available year), comprising amount in currency, as quoted by the profiled company itself. = increase in revenue over the previous year or = decrease in revenue. The profiled company s main treatment subject areas (and areas of R&D). A mission statement from the profiled company. how the company has performed at the six indicators of corporate reputation The profiled company s performance at the six indicators of corporate reputation in 2015, according to the diabetes patient groups familiar with the company. The profiled company s performance at the six indicators of corporate reputation, according to the diabetes patient groups that have worked with the company. How the profiled company performed among diabetes patient groups for different countries/regions, compared with the company s global averages for diabetes patient groups in how the company ranks for corporate reputation compared with other companies The profiled company s rankings among diabetes patient groups in 2015 for the six indicators of corporate reputation, compared with 20 other companies. The profiled company s rankings worldwide in 2015 for the six indicators of corporate reputation, compared with 47 other companies. profile of the patient groups familiar with the company Other companies that partner with a significant number of the profiled company s partner patient groups. The countries of the patient groups familiar with the profiled company. Janssen Pharmaceutical Companies of Johnson & Johnson
6 Contact details PatientView Registered office: One Fleet Place, London, EC4M 7WS, UK Tel: +44-(0) Registered in England, number: Data protection registration number: Z VAT registration number: GB Copyright 2016 PatientView Ltd. All rights reserved. This booklet is the property of PatientView, and no part may be reproduced without permission, or passed on to any third party without the permission of PatientView.
John Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
More informationUS pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
More informationPBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
More informationTABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
More informationGlobal Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationBRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
More informationOrgan Transplantation Market Research Report- Global Forecast Till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 27.08.2015 NEW DRUG S. NAME OF APPLICANT DIARY TYPE OF 1. M/S. INTAS PHARMACEUTICALS LIMITED - CT NOC (2) 2. M/S. PFIZER LIMITED - QUERY 3. M/S. MSN LABORATORIES - ADDITIONAL SITE 4. M/S.
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationInfluenza Vaccination Market Research Report Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR
More informationCOPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global
COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and
More informationTHINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd
THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd Disclosures Associate Professor in the Alzheimer Center at the VU
More informationPancreatic Cancer Market Research Report- Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1638 Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report / Search Code: MRFR/HC/1107-HCRR Publish
More informationRussian pharmaceutical market: 2016 vs Anna Ermolaeva AlphaRM General Manager
Russian pharmaceutical market: 2016 vs 2017 Anna Ermolaeva AlphaRM General Manager Russian pharmaceutical market volume 16 ~1,13 (trln, RUB)* & ~5,3 (bln, units) Including Food Supplements (FS), Medical
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
More informationGlobal Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023
Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Psoriasis Pipeline Drugs Industry Sizing, Growth and Forecast
More informationInsights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
More informationVascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
More informationANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More information2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
More informationREFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013
REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013 Executive Summary Diovan (valsartan): Key Metrics in the Seven Major Pharmaceutical Markets* 2012 Market Sales US - Diovan 5EU - Diovan Japan - Diovan
More informationAmerican Association for Cardiovascular and Pulmonary Rehabilitation (AACVPR)
Organizations Supporting the Preventive Health Savings Act Academy of Nutrition and Dietetics ACT The App Association Aetna Alliance for Aging Research Allscripts Alzheimer s Association Alzheimer s Impact
More informationREFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets
More informationAward of Contracts without Competition December 2013
SERIVCES 2850 Open Text Opentext Web CMS Software Support 125,000.00 Business Services Organisation 2259 Lynas Cooked Pork (Lynas) 63,063.00 2703 Limavady Office Products 169,477.00 2817 Merck no 3 Nutritional
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationCurrent and future market dynamics overview
OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast
More informationOrencia (Rheumatoid Arthritis)
Orencia (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1006DFR / Published November 2012 Executive Summary Orencia: Key Metrics in Rheumatoid Arthritis Markets 2012 Orencia Sales Total 7 MM $831m
More informationIndustry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
More informationGLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS HLC029D January 2013 Paul Evers Project Analyst ISBN: 0-89336-238-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationREFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS Executive Summary Sales for Parkinson s Disease Market The Parkinson s disease market in the US,
More informationBoston University Expert Review Meeting on the Evaluation of Novartis Access
Boston University Expert Review Meeting on the Evaluation of Novartis Access Principal Investigator: Richard Laing Co-investigators: Peter Rockers, Veronika Wirtz, Taryn Vian, Monica Onyango, Paul Ashigbie
More informationSupporting patient groups: a pharmaceutical company perspective Susanna Leto di Priolo Novartis Oncology Region Europe
Supporting patient groups: a pharmaceutical company perspective Susanna Leto di Priolo Novartis Oncology Region Europe Why pharmaceutical companies collaborate with patient groups Challenges Position on
More informationMEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:
MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS PHM154A September 2013 Anand Gijare Project Analyst ISBN: 1-56965-544-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More informationREFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major
More informationin patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy
More informationJAK AND PI3K SIGNALING PATHWAY MARKETS
JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationREGISTER OF INTERESTS SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes Published: 29 November 2017
CHAIR John Petrie, Professor of Diabetic Medicine Financial Non-financial Non-personal Last updated Specific Non-Specific Specific Non- Specific Professor of Diabetic Medicine, University of Glasgow Academic.
More informationREFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) Executive Summary Nimenrix: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan
More informationREFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG Executive Summary Sales for Chronic Heart Failure in the Japan The Japan Chronic heart failure (CHF) therapeutics
More informationGlobal HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )
Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United
More informationINCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationDIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC)
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC) R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p
More informationCHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
More informationPresenter Disclosure
Presenter Disclosure Linong Ji.M.D Consulting and lecture fee Eli Lilly, Bristol-Myers Squibb, Novartis, Novo Nordisk, Merck, Bayer, Takeda, Sanofi-Aventis, GlaxoSmithKline, Roche, Johnson & Johnson, boehinger
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationEurope Ginseng Market Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Europe Ginseng Market Report 2016 Europe Ginseng Market Report 2016 Publication ID: QYR12167206 Publication December
More informationDiabetic Retinopathy Treatment - Global Market Outlook ( )
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022) Diabetic Retinopathy Treatment - Global Market
More informationQuality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro
Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro Introduction Human medicines Cosmetics Veterinary medicines Medical devices
More informationTarget Audience. approach this patient case scenario, including identifying an
Activity Overview In this case-based webcast, meet LaWanda, a 57-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 8.4%, she is currently taking basal insulin and fast-acting insulin,
More informationSUPPLEMENTARY DATA. Telediab Study Group :
Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète
More informationKenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
More informationCardiac Monitoring: Market and Outsourcing Dynamics. October, 2014
Cardiac Monitoring: Market and Outsourcing Dynamics October, 2014 Introduction act with confidence Table of Contents Copyright and usage guidelines... 4 Introduction...5 Differentiating dedicated cardiac
More informationActemra (Rheumatoid Arthritis)
Actemra (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1007DFR / Published November 2012 Executive Summary Actemra: Key Metrics in Rheumatoid Arthritis Markets 2012 Actemra Sales Total 7 MM $355m
More informationGLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationREFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 BRODALUMAB (PSORIASIS) - Executive Summary Table below presents key metrics for brodalumab in seven of the nine major pharmaceutical markets covered
More informationREFERENCE CODE GDHCER PUBLICAT ION DATE M AY 2015 GLAUCOMA EPIDEMIOLOGY FORECAST TO 2023
REFERENCE CODE GDHCER081-15 PUBLICAT ION DATE M AY 2015 GLAUCOMA Executive Summary Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye s optic nerve, resulting in progressive,
More informationnephropathy and/or chronic kidney disease Summary of recommendations
July 2017 Guidelines: Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients
More informationEvidence grades for the recommendations
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy
More informationBoehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence
Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim
More informationHIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),
More informationtaking at (Jan. 21, 2016) by Older 2016.pdf).
HSGAC MINORITY STAFF REPORT MANUFACTURED CRISIS How Devastating Drug Increases Are Harming America s Seniors U.S. Senate Homeland Security & Governmental Affairs Committee, Minority Office Page 1 EXECUTIVE
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationMS Trust Comments on the ACD
MS Trust Comments on the ACD Name xxxxxxxxxxx Role other Other role xxxxxxxxxxxxxxxxxx Location England Conflict no Notes Comments on individual sections of the ACD: Section 1 The MS Trust maintains that
More informationREFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
More informationTHYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...
More informationRESOLUCIÓN N DE LA ONU SOBRE EL PAPEL DE LA ATENCIÓN N PRIMARIA EN LAS ENFERMEDADES CRÓNICAS
RESOLUCIÓN N DE LA ONU SOBRE EL PAPEL DE LA ATENCIÓN N PRIMARIA EN LAS ENFERMEDADES CRÓNICAS IV Congreso Nacional de Atención Sanitaria al Paciente Crónico 9 de Marzo de 2012 Alicante, Spain Richard G.
More informationSUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84
CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:
More informationClinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany
Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Conflict of Interest Statement German Research Council German Ministry
More informationChina Oral Hypoglyceimic Agents (OHAs) Industry Report, Feb. 2011
China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010 Feb. 2011 This report Analyzes the status quo and prospect of Chinese OHAS Market. Related Products China Interventional Cardiovascular Device
More informationClinical impact of practice registers in Bourgogne and Rhône Alpes
Clinical impact of practice registers in Bourgogne and Rhône Alpes Dr Yannick Béjot The Dijon Stroke Registry EA4184, University Hospital and Medical School of Dijon, France Dr Carlos El KHOURY c.elkhoury@ch-vienne.fr
More informationREFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major
More informationREFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major
More informationQuality Medical Donations
PQMD members played an active role in relief efforts following devastating floods left by Hurricane s Harvey, Irma, and Maria. PQMD Community of Practice: Connect Convene - Catalyze Are you an engaged
More informationKaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013
Kaletra (HIV) Forecast and Market Analysis to 2022 GDHC1051DFR/ Published January 2013 Executive Summary Kaletra Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US - Kaletra 5EU
More informationRituxan (Rheumatoid Arthritis)
Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1008DFR / Published November 2012 Executive Summary Rituxan: Key Metrics in Rheumatoid Arthritis Markets 2012 Rituxan Sales Total 7 MM $835m
More informationAbstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
More informationSave Up To $125 with Early Bird Rates through August 21!
Save Up To $125 with Early Bird Rates through August 21! Experience BIG IDEAS, KEY STRATEGIES, and PRACTICAL TAKEAWAYS that will help transform how you deliver patient care! REGISTER TODAY! accc-cancer.org/oncologyconference
More informationThis is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced.
This is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/102808/
More informationREFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - Executive Summary Menomune: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU
More informationCognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015 Cognitive Impairment Associated
More informationPatient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels Bertrand Cariou, 1 Maja Bujas-Bobanovic, 2 Michael J Louie,
More informationVisceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research
Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research The global visceral pain market size was estimated at USD 9.51 billion in 2016 and is expected to
More informationGlobal Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage
Global Influenza Drugs and Vaccines Market By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent): Analysis By Region, By Country: Opportunities and Forecast (2016-2021)
More informationVaccine Technologies and Global Markets
A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious
More informationMolecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research
Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research " Projected to grow at a CAGR of almost 9% from 2016 to 2024, the molecular diagnostics market
More informationBoehringer Ingelheim and investment in R&D. Volker Barkmann
Boehringer Ingelheim and investment in R&D Volker Barkmann I. Our Corporation Boehringer Ingelheim in brief Boehringer Ingelheim Center Our headquarters in Ingelheim, Germany Family-owned global corporation
More informationChronic illness is a growing market for Novo Nordisk
Chronic illness is a growing market for Novo Nordisk Aslam Dalvi - Associate Portfolio Manager Denmark-based global healthcare company Novo Nordisk traces its origins to the first pioneers in insulin production
More informationAntifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles
Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin,
More informationAdherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research
More informationStroke and Headache Headache and Stroke
Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin
More informationTABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More informationREFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 PARKINSON S DISEASE - EPIDEMIOLOGY FORECAST TO 2022
REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 Executive Summary Parkinson s disease is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer s
More informationSimilar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
More informationEmergency Response The People Perspective
Emergency Response The People Perspective Abigail Pollard Managing Director Blake Emergency Services 5 th March 2015 Incidents have a dramatic effect on people Internet Library How a company responds and
More information2017 ICF GLOBAL CONSUMER AWARENESS STUDY
2017 ICF GLOBAL CONSUMER AWARENESS STUDY EXECUTIVE SUMMARY 2017 ICF Global Consumer Awareness Study: Executive Summary 1 2017 ICF GLOBAL CONSUMER AWARENESS STUDY EXECUTIVE SUMMARY Contents 03 Introduction
More informationAFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.
More informationTHE VALUE OF TREATMENT FOR BRAIN DISORDERS A NEW VISION IN PROGRESS...
V T THE VALUE OF TREATMENT FOR BRAIN DISORDERS A NEW VISION IN PROGRESS... BRIEF DESCRIPTION The European Brain Council (EBC) is carrying out a new research project for 2015-2017 on The value of treatment
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More information